Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications.
Subjects with metabolic syndrome--a constellation of cardiovascular risk factors of which central obesity and insulin resistance are the most characteristic--are at increased risk for developing diabetes mellitus and cardiovascular disease. In these subjects, abdominal adipose tissue is a source of inflammatory cytokines such as tumor necrosis factor-alpha, known to promote insulin resistance. The presence of inflammatory cytokines together with the well-documented increased risk for cardiovascular diseases in patients with inflammatory arthritides and systemic lupus erythematosus has prompted studies to examine the prevalence of the metabolic syndrome in an effort to identify subjects at risk in addition to that conferred by traditional cardiovascular risk factors. These studies have documented a high prevalence of metabolic syndrome which correlates with disease activity and markers of atherosclerosis. The correlation of inflammatory disease activity with metabolic syndrome provides additional evidence for a link between inflammation and metabolic disturbances/vascular morbidity.
Sidiropoulos
Prodromos I
PI
Department Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, 1, Voules Str, Heraklion 71110, Greece. sidiropp@med.uoc.gr
Karvounaris
Stylianos A
SA
Boumpas
Dimitrios T
DT
D000818:Animals; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology*; D012216:Rheumatic Diseases / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology*; D012307:Risk Factors